Mycobacterium tuberculosis Molecular Determinants of Infection, Survival Strategies, and Vulnerable Targets
- PMID: 29389854
- PMCID: PMC5874743
- DOI: 10.3390/pathogens7010017
Mycobacterium tuberculosis Molecular Determinants of Infection, Survival Strategies, and Vulnerable Targets
Abstract
Mycobacterium tuberculosis is the causative agent of tuberculosis, an ancient disease which, still today, represents a major threat for the world population. Despite the advances in medicine and the development of effective antitubercular drugs, the cure of tuberculosis involves prolonged therapies which complicate the compliance and monitoring of drug administration and treatment. Moreover, the only available antitubercular vaccine fails to provide an effective shield against adult lung tuberculosis, which is the most prevalent form. Hence, there is a pressing need for effective antitubercular drugs and vaccines. This review highlights recent advances in the study of selected M. tuberculosis key molecular determinants of infection and vulnerable targets whose structures could be exploited for the development of new antitubercular agents.
Keywords: Mycobacterium tuberculosis; antitubercular drugs; drug discovery; target identification; tuberculosis.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures

Similar articles
-
[Recent progress in mycobacteriology].Kekkaku. 2007 Oct;82(10):783-99. Kekkaku. 2007. PMID: 18018602 Japanese.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
[Frontier of mycobacterium research--host vs. mycobacterium].Kekkaku. 2005 Sep;80(9):613-29. Kekkaku. 2005. PMID: 16245793 Japanese.
-
Insights into development of Decaprenyl-phosphoryl-β-D-ribose 2'-epimerase (DprE1) inhibitors as antitubercular agents: A state of the art review.Indian J Tuberc. 2022 Oct;69(4):404-420. doi: 10.1016/j.ijtb.2021.09.003. Epub 2021 Sep 10. Indian J Tuberc. 2022. PMID: 36460369 Review.
-
Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.Biomed Pharmacother. 2018 Jul;103:1733-1747. doi: 10.1016/j.biopha.2018.04.176. Biomed Pharmacother. 2018. PMID: 29864964 Review.
Cited by
-
Interrogating the substrate specificity landscape of UvrC reveals novel insights into its non-canonical function.Biophys J. 2022 Aug 16;121(16):3103-3125. doi: 10.1016/j.bpj.2022.07.012. Epub 2022 Jul 9. Biophys J. 2022. PMID: 35810330 Free PMC article.
-
Mycobacterium tuberculosis Uses Mce Proteins to Interfere With Host Cell Signaling.Front Mol Biosci. 2020 Jan 8;6:149. doi: 10.3389/fmolb.2019.00149. eCollection 2019. Front Mol Biosci. 2020. PMID: 31998747 Free PMC article. Review.
-
Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment.Pathogens. 2020 May 18;9(5):385. doi: 10.3390/pathogens9050385. Pathogens. 2020. PMID: 32443469 Free PMC article.
-
The American Association of Tissue Banks tissue donor screening for Mycobacterium tuberculosis-Recommended criteria and literature review.Transpl Infect Dis. 2024 Nov;26 Suppl 1(Suppl 1):e14294. doi: 10.1111/tid.14294. Epub 2024 Jun 9. Transpl Infect Dis. 2024. PMID: 38852068 Free PMC article. Review.
-
Structural characterization of glycinamide-RNase-transformylase T from Mycobacterium tuberculosis.Emerg Microbes Infect. 2020 Jan 2;9(1):58-66. doi: 10.1080/22221751.2019.1707716. eCollection 2020. Emerg Microbes Infect. 2020. PMID: 31894729 Free PMC article.
References
-
- WHO | Tuberculosis (TB) [(accessed on 30 December 2017)]; Available online: http://www.who.int/gho/tb/en/
-
- WHO | Global Tuberculosis Report 2017. [(accessed on 30 December 2017)]; Available online: http://www.who.int/tb/publications/global_report/en/
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources